European equities rallied on Thursday, closing nearly 1 percent higher as investors reacted to a raft of corporate earnings and fresh economic data.» Read More
Marijn Dekkers, CEO of Bayer, explains to CNBC that while Bayer has felt increased pressure on drug pricing from governments, its success in research and development has the company positioned for success.
Bayer CEO Marijn Dekkers says the firm's $1.2 billion purchase of Schiff Nutrition will help Bayer build its position in consumer healthcare.
*Cheuvreux cuts Bayer to outperform from selected list. Reuters Station users, click. 1568. Reuters Station users, click. 4899.
*Jefferies cuts AstraZeneca PLC price target to 3,000 p from 3,100 p;. *Jefferies raises Bayer AG price target to 71 euros from 65 euros;. *Jefferies raises Eli Lilly price target to $36 from $35; rating.
FRANKFURT, Oct 9- Bayer AG:. *Says European commission gives green light for flexyess. *Says health authorities of the EU member states will grant national approvals.
Shares in CIMB Thai Bank Pcl jumped as much as 23 percent to 2.96 baht, the highest since Nov. 5, 2010, after a newspaper reported that its parent, CIMB Group Holdings Bhd, planned to buy a stake in Bank of Ayudhya.
DEUTSCHE TELEKOM Indicated 0.1 percent lower. Deutsche Telekom is in talks to merge its T-Mobile USA unit with smaller rival MetroPCS, in a move that could pave the way for the German company to eventually exit the U.S. wireless market.
WASHINGTON, Oct 2- U.S. antitrust regulators found no wrongdoing in a deal made four years ago between German drugmaker Bayer AG and a division of Teva Pharmaceuticals to end patent litigation over the popular Yasmin birth control pill.
Irene Tse, who headed the North America operations of the Chief Investment Office, told the firm she is resigning to focus on "entrepreneurial ventures," according to a memo on Monday from Chief Operating Officer Matt Zames, a copy of which was obtained by Reuters.
He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa. A top Morgan Stanley broker, Jonathan Madrigano, who last year managed about $2 billion in client assets left the company's brokerage division on Friday to join J.P. Morgan Securities.
The bank named Tom Willett as head of mergers and acquisitions, Europe. He will be based in London. Willett joins from Royal Bank of Scotland, where most recently he was chairman of corporate finance for Europe, the Middle East and Africa.
FRANKFURT, Oct 1- Evotec AG:. *Evotec and Bayer enter into multi-target alliance to fight endometriosis. up to approximately euro 580 million.
When we began planning our special report "Women in Business," I was eager to learn about how women are really doing in the workplace. In short, many women are successful, powerful and well off, but progress in the professional world has stalled.
With both global food prices and concerns about food safety on the rise, technology is playing a more important role in the economics of the world’s food supply.
An airplane needs to be safe in order for passengers to board it. Likewise, an airline CEO wants to feel the same clarity and certainty that so many of his c-suite compadres do in order to sustain growth.
European shares are indicated to open flat Friday, ahead of a conference at the European Central Bank in Frankfurt where Fed Chairman Ben Bernanke and ECB President Jean-Claude Trichet will both speak.
The jobs crisis has brought an unwelcome discovery for many unemployed Americans: job openings in their old fields exist. Yet they no longer qualify for them.
Shares in European airline and travel stocks fell heavily on Monday as ash from an Icelandic volcano looked set to bring much of Europe to a standstill for a 5th straight day.
I didn’t inhale. It’s the truth. I swear. I have never ever taken a toke on a joint or even a cigarette. Growing up, my parents were both smokers and I think I developed such a distaste for the constant cloud that it just never held any appeal for me.
At the risk of getting more emails from conspiracy-theorist readers who think I report too much negative news about Pfizer, here comes another setback for the world's biggest drug company.